EDIT - Editas Medicine, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
3.66 0.45 (12.3%)	---	0.0 (0.0%)	-0.04 (-0.92%)	0.03 (0.82%)	0.36 (9.78%)	0.05 (1.23%)	0.05 (1.23%)

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Market Period: Closed

Earnings & Ratios

Basic EPS:: -0.63
Diluted EPS:: -0.63
Basic P/E:: -6.5238
Diluted P/E:: -6.5238
RSI(14) 1m:: 0.0
VWAP:: 4.11
RVol:: 1.3711

Events

Period	Kind	Movement	Occurred At
1m	Price increase 1m	4.17 +0.05 (+1.22%)	Oct 15 18:55
1m	Price increase 1m	3.95 +0.04 (+1.02%)	Oct 15 11:42
1m	Price decrease 1m	3.92 -0.04 (-1.01%)	Oct 15 11:34
1m	Price increase 1m	4.08 +0.04 (+1.12%)	Oct 15 10:13
Day	Price increase day	4.03 +0.37 (+10.11%)	Oct 15 10:02